Carfilzomib prevented BCMA degradation, increased target density, and improved CAR T susceptibility by ~26%–28% in vitro, while enhancing xenograft antitumor activity without worsening T-cell ...

TOKYO & MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and ...

The firm will provide manufacturing and regulatory support as UW prepares an IND submission for its GD2 CAR T-cell therapy.

We owe a lot to tissue resident memory T cells (T RM). These specialized immune cells are among the body's first responders to disease. Rather than coursing through the bloodstream-as many T cells ...